Piermont Capital Management’s United Therapeutics UTHR Stock Holding History

Piermont Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-24,300	Closed	-$2.75M	–	207
2018 Q2	$2.75M	Buy	24,300 +18,230	+300%	+$2M	0.84%	40
2018 Q1	$682K	Sell	6,070 -290	-5%	-$36.8K	0.23%	129
2017 Q4	$941K	Buy	6,360 +3,860	+154%	+$491K	0.31%	112
2017 Q3	$293K	Sell	2,500 -590	-19%	-$75.3K	0.1%	222
2017 Q2	$401K	Buy	+3,090	New	+$385K	0.11%	237
2016 Q2	–	Sell	-2,350	Closed	-$262K	–	283
2016 Q1	$262K	Hold	2,350	–	–	0.08%	214
2015 Q4	$368K	Hold	2,350	–	–	0.12%	185
2015 Q3	$308K	Hold	2,350	–	–	0.1%	194
2015 Q2	$409K	Hold	2,350	–	–	0.12%	184
2015 Q1	$405K	Buy	+2,350	New	+$358K	0.12%	184

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Piermont Capital Management's UTHR Position: Q3 2018 in Review

Piermont Capital Management sold out of United Therapeutics (UTHR) in Q3 2018, closing a stake of 24,300 shares — an estimated $2.75M sold.

Piermont Capital Management first reported a position in UTHR in Q1 2015 and held it in 10 quarters. The position peaked at $2.75M in Q2 2018. 367 funds tracked by Wall St. Rank hold UTHR as of Q3 2018.

Piermont Capital Management reported no remaining United Therapeutics position as of Q3 2018 after selling out during the quarter.
Piermont Capital Management sold 24,300 United Therapeutics shares in Q3 2018, an estimated $2.75M.
Piermont Capital Management first reported a position in United Therapeutics in Q1 2015 and held it in 10 quarters.
Piermont Capital Management's United Therapeutics position peaked at $2.75M in Q2 2018.
367 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.